latest news releases from the newsroom
Movero Technology Launches Reseller Channel for Authorized Agents
LAS VEGAS, April 4, 2006 (PRIMEZONE) -- Movero Technology, Inc. (www.moverotech.com), a provider of comprehensive products and solutions for a wide range of wireless enterprise users, today announced a plan to create new opportunities for mobile application and solution providers with its reseller channel, by helping vendors to easily bundle wireless devices and plans with their products.
JetBlue Airways Corporation
Photo Release -- JetBlue and Bliss Spa Say Buh-Bye to Red-Eye, Hello to Shut-Eye Service
NEW YORK, April 4, 2006 (PRIMEZONE) -- JetBlue Airways Corp. (Nasdaq:JBLU), New York's hometown airline, and bliss, New York's hottest spa have partnered to create a unique experience for value-seekers on the low-fare airline's overnight flights from the West. Commonly known as "red-eye" flights after the state of customers upon arrival, the low-fare airline and industry-leading urban day spa, known for its fun approach to beauty, have developed Shut-Eye, an onboard experience that leaves customers feeling refreshed and ready to meet the day.
Amazon Biotech, Inc.
Amazon Biotech Announces Development of a Redesigned HIV Protocol to Test AMZ0026 as an Add-On to Conventional HAART Therapy in HIV-1 Seropositive Pre-AIDS Subjects
NEW YORK, April 4, 2006 (PRIMEZONE) -- Amazon Biotech, Inc. (OTCBB:AMZB) today announced that it is redesigning its protocol for phase I/II trials to test AMZ0026 as an antiviral and immunomodulatory agent in HIV positive subjects receiving Highly Active Anti-Retroviral Therapy (HAART). The current study design includes 32 non-symptomatic HIV positive subjects who are currently treated with HAART (highly active anti-retroviral therapy) therapy regimens, commonly known as cocktail therapies, whereby 50% of the subjects will be continuing their current HAART regimen without change, and 50% will receive AMZ0026 along with their existing HAART regimen. The new study will entail six months treatment with monitoring of "T" cell increases, HIV plasma viral load decreases, and improvements in quality of life.